About
Dexcel Pharma is a pharmaceutical company engaged in the discovery, development, manufacture, and commercialization of innovative pharmaceutical products based on its proprietary controlled-release technologies. Dexcel Pharma develops novel formulations of existing molecules for large therapeutic markets. The companys aim is to provide meaningful clinical benefits for patients with chronic diseases. For example, the companys PerioChip product offers a new approach to treating gum disease by using a small chip inserted under the gums. Dexcel Pharmas development pipeline includes more than 30 novel 505(b)2 formulations and complex generics, targeting markets in the U.S. and the EU.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was Dexcel Pharma founded?
- Dexcel Pharma was founded in January 1965.
- What is Dexcel Pharma's primary business focus?
- Dexcel Pharma focuses on the discovery, development, manufacture, and commercialization of innovative pharmaceutical products using its proprietary controlled-release technologies, including novel formulations of existing molecules and complex generic drugs.
- How many employees does Dexcel Pharma have?
- Dexcel Pharma has over 500 employees, with an exact count of 521.
- Where is Dexcel Pharma's headquarters located?
- Dexcel Pharma's headquarters is located in Yokne'am Illit, Israel.
- What is an example of a product developed by Dexcel Pharma?
- Dexcel Pharma developed PerioChip, a product that treats gum disease using a small chip inserted under the gums.
- What is the status of Dexcel Pharma's development pipeline?
- Dexcel Pharma's development pipeline includes more than 30 novel 505(b)2 formulations and complex generics, targeting markets in the U.S. and the EU.
- In which countries does Dexcel Pharma have offices outside of Israel?
- Dexcel Pharma has offices in Germany (Alzenau), the United Kingdom (Daventry), and Singapore.
- What was a notable partnership for Dexcel Pharma in 2014?
- In April 2014, Kitov Pharma signed a deal with Dexcel Pharma concerning a hypertension drug.